A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dociparstat sodium in combination with standard chemotherapy for the treatment of ACTIVEly-diagnosed acute myeloid leukemia Read more
A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome? Read more
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen. Read more
A Phase 1b Dose Escalation Study Of Lemzoparlimab (TJ011133) In Combination With Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Read more
A Phase 1/2 Study Of Alx148 In Combination With Azacitidine In Patients With Higher Risk Mds Read more
A Phase 1-2 Pharmacokinetic Guided Dose-Escalation And Dose-Confirmation Study Of ASTX727, A Combination Of The Oral Cytidine Deaminase Inhibitor (Cdai) E7727 With Oral Decitabine In Subjects With Myelodysplastic Syndromes (MDS) Read more
This Is A Single-Arm, Open-Label, Multicenter, Non- Randomized Interventional Study To Evaluate The Pharmacokinetic (PK) Interaction, Safety, And Preliminary Efficacy Of ASTX727 When Given In Combination With Venetoclax For The Treatment Of Actively Diagnosed Acute Myeloid Leukemia (AML) In Adults Who Are Age 75 Years Or Older, Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. Read more
Phase II Trial Of Intravesical Gemcitabine And MK-3475 (Pembrolizumab) In The Treatment Of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Read more
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib In Combination With Nivolumab To Tivozanib In Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines Of Therapy, One Of Which Is An Immune Checkpoint Inhibitor Read more
